Drug-induced parkinsonism

Bibliography

• Anton-Stephens D. Preliminary observations on the psychiatric uses of chlorpromazine (Largactil). J Ment Sci 1954;100(419):543-57
   PubMed Web of Science ®Google Scholar
• Goldman D. Treatment of psychotic states with chlorpromazine. J Am Med Assoc 1955;157(15):1274-8
   PubMed Web of Science ®Google Scholar
• Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-60
   PubMed Web of Science ®Google Scholar
• Hall RA, Jackson RB, Swain JM. Neurotoxic reactions resulting from chlorpromazine administration. J Am Med Assoc 1956;161(3):214-18
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon JL, Mena MA, de Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012;29(2):105-18
   PubMed Web of Science ®Google Scholar
• Errea-Abad JM, Ara-Callizo JR, Aibar-Remon C. Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease. Rev Neurol 1998;27(155):35-9
   PubMed Web of Science ®Google Scholar
• Vazquez-Alen P, Perez-Gilabert Y, Mateo D, Gimenez-Roldan S. A study made on a data base of 2,471 patients with Parkinson disease and disorders of movement in Health District 1 of the autonomous region of Madrid. Observed demographic changes over 8 year-period. Rev Neurol 2000;30(7):635-40
   PubMed Web of Science ®Google Scholar
• Lorberboym M, Treves TA, Melamed E, et al. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006;21(4):510-14
   PubMed Web of Science ®Google Scholar
• Rollema H, Skolnik M, D'Engelbronner J, et al. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994;268(1):380-7
   PubMed Web of Science ®Google Scholar
• Mena MA, Garcia de Yebenes MJ, Tabernero C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;18(5):410-26
   PubMed Web of Science ®Google Scholar
• Hoenicka J, Vidal L, Morales B, et al. Molecular findings in familial Parkinson disease in Spain. Arch Neurol 2002;59(6):966-70
   PubMed Web of Science ®Google Scholar
• Marti Masso JF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 1996;11(1):10-15
   PubMedGoogle Scholar
• Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 1994;150(11):757-62
   PubMedGoogle Scholar
• Vingerhoets FJ, Snow BJ, Tetrud JW, et al. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994;36(5):765-70
   PubMed Web of Science ®Google Scholar
• Mahlknecht P, Stockner H, Kiechl S, et al. Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease? Mov Disord 2012;27(9):1194-6
   PubMedGoogle Scholar
• Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012;8(1):15-21
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-20
   PubMed Web of Science ®Google Scholar
• Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006;21(6):800-8
   PubMed Web of Science ®Google Scholar
• Marti-Masso JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998;13(3):453-6
   PubMed Web of Science ®Google Scholar
• Noyes K, Liu H, Holloway RG. What is the risk of developing parkinsonism following neuroleptic use? Neurology 2006;66(6):941-3
   PubMed Web of Science ®Google Scholar
• Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005;165(16):1882-8
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006;39(1):9-12
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18(5):432-40
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 2005;20(3):187-99
   PubMedGoogle Scholar
• Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160(8):1396-404
   PubMed Web of Science ®Google Scholar
• Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15(1):33-48
   PubMedGoogle Scholar
• Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003;28(Suppl 1):39-51
   PubMed Web of Science ®Google Scholar
• Carlsson A. The mechanism of action of neuroleptics and antidepressive drugs. Lakartidningen 1965;62(25):1978-90
   PubMedGoogle Scholar
• Pollak P, Gaio JM, Hommel M, et al. Effects of tiapride in tardive dyskinesia. Psychopharmacology (Berl) 1985;85(2):236-9
   PubMed Web of Science ®Google Scholar
• Nakajima Y, Kondo T, Narabayashi H. Long-term evaluation of tiapride in patients with various forms of dyskinesia. No To Shinkei 1985;37(10):1013-19
   PubMedGoogle Scholar
• Naito Y, Kuzuhara S. Parkinsonism induced or worsened by cisapride. Nihon Ronen Igakkai Zasshi 1994;31(11):899-902
   PubMedGoogle Scholar
• Lees AJ, Lander CM, Stern GM. Tiapride in levodopa-induced involuntary movements. J Neurol Neurosurg Psychiatry 1979;42(4):380-3
   PubMed Web of Science ®Google Scholar
• Lang AE, Sandor P, Duff J. Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol 1995;18(1):39-45
   PubMed Web of Science ®Google Scholar
• Gerlach J, Casey DE. Remoxipride, a new selective D2 antagonist, and haloperidol in Cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1990;14(1):103-12
   PubMed Web of Science ®Google Scholar
• Dufour H, Castelli J, Luccioni H, et al. A new substituted benzamide with neuroleptic effects: lin 14 18 or sultopride. Encephale 1975;1(1):15-18
   PubMedGoogle Scholar
• Benazzi F. Side-effects of benzamide derivatives. Int J Geriatr Psychiatry 1997;12(1):132
   PubMed Web of Science ®Google Scholar
• Ross RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci 1990;17(2):155-62
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Gras-Champel V, Douadi Y, et al. Trimetazidine - a new aetiology for extrapyramidal disorders: a case of parkinsonism and akathisia. Therapie 2005;60(6):603-5
   PubMed Web of Science ®Google Scholar
• Marti Masso JF, Marti I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005;60(4):419-22
   PubMed Web of Science ®Google Scholar
• Marti Masso JF. Trimetazidine-induced parkinsonism. Neurología 2004;19(7):392-5
   PubMed Web of Science ®Google Scholar
• Briani C, Cagnin A, Chierichetti F, et al. Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade. Eur J Neurol 2004;11(10):709-10
   PubMed Web of Science ®Google Scholar
• Edelstein H, Knight RT. Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet 1987;2(8554):341-2
   PubMed Web of Science ®Google Scholar
• Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. Q J Med 1986;59(230):549-56
   PubMedGoogle Scholar
• Sempere AP, Duarte J, Cabezas C, et al. Aggravation of parkinsonian tremor by cisapride. Clin Neuropharmacol 1995;18(1):76-8
   PubMed Web of Science ®Google Scholar
• Giladi N, Melamed E. Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Mov Disord 1999;14(1):158-9
   PubMed Web of Science ®Google Scholar
• Sommet A, Azais-Vuillemin C, Bagheri H, et al. Trimetazidine: a new cause for drug-induced parkinsonism? Mov Disord 2005;20(8):1080-1
   PubMed Web of Science ®Google Scholar
• Veitch K, Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol 1994;45(1):158-63
   PubMed Web of Science ®Google Scholar
• Tort AB, Dall'Igna OP, de Oliveira RV, et al. Atypical antipsychotic profile of flunarizine in animal models. Psychopharmacology (Berl) 2005;177(3):344-8
   PubMed Web of Science ®Google Scholar
• Sawada Y, Nasu R, Matsuo H, Ohtani H. Relationship between structure and drug-induced parkinsonism. Ann Pharmacother 2000;34(5):668
   PubMed Web of Science ®Google Scholar
• Petri H, Leufkens H, Naus J, et al. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990;43(5):433-9
   PubMed Web of Science ®Google Scholar
• Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 1997;12(1):107-10
   PubMed Web of Science ®Google Scholar
• Negrotti A, Calzetti S, Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 1992;13(1):261-4
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994;8(4):293-306
   PubMed Web of Science ®Google Scholar
• Micheli F, Pardal MF, Gatto M, et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 1987;37(5):881-4
   PubMed Web of Science ®Google Scholar
• Micheli FE, Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989;4(2):139-46
   PubMed Web of Science ®Google Scholar
• Meyboom RH, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986;2(8501):292
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Kohara N, Ohkawa Y, et al. Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade–report of 31 cases. Rinsho Shinkeigaku 1989;29(6):681-6
   PubMedGoogle Scholar
• Kariya S, Isozaki S, Masubuchi Y, et al. Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 1995;50(10):1645-50
   PubMed Web of Science ®Google Scholar
• Hefner R, Fischer PA. Increase in Parkinson symptoms caused by calcium antagonists. Nervenarzt 1989;60(3):187-8
   PubMedGoogle Scholar
• Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 2004;62(3B):784-8
   PubMed Web of Science ®Google Scholar
• Di Rosa AE, Morgante L, Meduri M, et al. Parkinson-like side effects during prolonged treatment with flunarizine. Funct Neurol 1987;2(1):47-50
   PubMedGoogle Scholar
• De Michele G, Filla A, Coppola N, et al. Extrapyramidal side-effects of flunarizine. Acta Neurol (Napoli) 1987;9(3):230-3
   PubMedGoogle Scholar
• Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother 1995;29(1):73-5
   PubMed Web of Science ®Google Scholar
• Claps A. Parkinson's disease secondary to flunarizine or other drugs. Rev Med Chil 1995;123(8):1033-6
   PubMedGoogle Scholar
• Chouza C, Scaramelli A, Caamano JL, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986;1(8493):1303-4
   PubMed Web of Science ®Google Scholar
• Benvenuti F, Baroni A, Bandinelli S, et al. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 1988;28(7):600-8
   PubMed Web of Science ®Google Scholar
• Baquero M, Dominguez-Sanz FJ, Burguera JA, et al. New forms of Parkinsonism in hospice care. Rev Neurol 1995;23(123):964-8
   PubMedGoogle Scholar
• Asanuma M, Ogawa N, Haba K, et al. Calcium antagonist flunarizine hydrochloride affects striatal D2 dopamine receptors in the young adult and aged rat brain. Arch Gerontol Geriatr 1991;13(3):271-8
   PubMed Web of Science ®Google Scholar
• Steck H. Extrapyramidal and diencephalic syndrome in the course of Largactil and Serpasil treatments. Ann Med Psychol (Paris) 1954;112(2 5):737-44
   PubMedGoogle Scholar
• Remblier C, Kassir A, Richard D, et al. Parkinson syndrome from diltiazem. Therapie 2001;56(1):57-9
   PubMed Web of Science ®Google Scholar
• Padrell MD, Navarro M, Faura CC, Horga JF. Verapamil-induced parkinsonism. Am J Med 1995;99(4):436
   PubMed Web of Science ®Google Scholar
• Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989;25(6):630-2
   PubMed Web of Science ®Google Scholar
• Matsui A, Matsuo H, Takanaga H, et al. Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J Pharmacol Exp Ther 1998;287(2):725-32
   PubMed Web of Science ®Google Scholar
• Malaterre HR, Renou C, Kallee K, Gauthier A. Akinesia and amiodarone therapy. Int J Cardiol 1997;59(1):107-8
   PubMed Web of Science ®Google Scholar
• Lombard M, Sarsfield P, Keogh JA. Adverse neurological response to amiodarone. Ir Med J 1986;79(3):71-2
   PubMedGoogle Scholar
• Dotti MT, Federico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995;10(2):233-4
   PubMed Web of Science ®Google Scholar
• Patten SB, Williams JV, Petcu R, Oldfield R. Delirium in psychiatric inpatients: a case-control study. Can J Psychiatry 2001;46(2):162-6
   PubMed Web of Science ®Google Scholar
• Muthane UB, Prasad BN, Vasanth A, Satishchandra P. Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. J Neurol Sci 2000;176(1):78-9
   PubMed Web of Science ®Google Scholar
• Miodownik C, Witztum E, Lerner V. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int J Psychiatry Med 2002;32(1):103-8
   PubMed Web of Science ®Google Scholar
• Dallocchio C, Mazzarello P. A case of Parkinsonism due to lithium intoxication: treatment with pramipexole. J Clin Neurosci 2002;9(3):310-11
   PubMed Web of Science ®Google Scholar
• Dolphin AC, Jenner P, Marsden CD. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Pharmacol Biochem Behav 1976;4(6):661-70
   PubMed Web of Science ®Google Scholar
• Brust JC. Substance abuse and movement disorders. Mov Disord 2010;25(13):2010-20
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28(4):188-90
   PubMed Web of Science ®Google Scholar
• Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 2004;6(3):153-68
   PubMed Web of Science ®Google Scholar
• Ricard C, Martin K, Tournier M, et al. A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 2005;31(1 Pt 1):98-101
   PubMed Web of Science ®Google Scholar
• Hauben M, Reich L. Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an "old" drug. Mov Disord 2005;20(3):387
   PubMed Web of Science ®Google Scholar
• Stadtland C, Erfurth A, Arolt V. De novo onset of Parkinson's disease after antidepressant treatment with citalopram. Pharmacopsychiatry 2000;33(5):194-5
   PubMed Web of Science ®Google Scholar
• Pina Latorre MA, Modrego PJ, Rodilla F, et al. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther 2001;26(2):111-12
   PubMed Web of Science ®Google Scholar
• Mendhekar DN, Benuiwal RP, Puri V. Parkinsonism and elevated lactic acid with sertraline. Can J Psychiatry 2005;50(5):301
   PubMed Web of Science ®Google Scholar
• Gregory RJ, White JF. Can sertraline induce Parkinson's disease? Psychosomatics 2001;42(2):163-4
   PubMed Web of Science ®Google Scholar
• Govoni S, Racchi M, Masoero E, et al. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Mol Psychiatry 2001;6(2):134-42
   PubMed Web of Science ®Google Scholar
• Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003;26(3):142-5
   PubMed Web of Science ®Google Scholar
• Arai M. Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran. J Neurol Neurosurg Psychiatry 2003;74(1):137-8
   PubMed Web of Science ®Google Scholar
• Sugiyama Y. Parkinsonism induced by propiverine hydrochloride–report of 3 cases]. Rinsho Shinkeigaku 1997;37(10):873-5
   PubMedGoogle Scholar
• Matsuo H, Matsui A, Nasu R, et al. Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. Pharm Res 2000;17(5):565-71
   PubMed Web of Science ®Google Scholar
• Garcia-Parajua P, Alvarez Iniesta I, Magarinos M. Reversible and dose-related parkinsonism induced by venlafaxine. Med Clin (Barc) 2003;120(19):759
   PubMed Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163(3):396-401
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-44
   PubMed Web of Science ®Google Scholar
• Liu Y, Peter D, Roghani A, et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992;70(4):539-51
   PubMed Web of Science ®Google Scholar
• Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 1992;89(22):10993-7
   PubMed Web of Science ®Google Scholar
• Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93(10):5166-71
   PubMed Web of Science ®Google Scholar
• Desmedt LK, Niemegeers CJ, Janssen PA. Anticonvulsive properties of cinnarizine and flunarizine in rats and mice. Arzneimittelforschung 1975;25(9):1408-13
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Mena MA, Penafiel N, De Yebenes JG. Cinnarizine-induced parkinsonism in primates. Clin Neuropharmacol 1992;15(2):152-4
   PubMed Web of Science ®Google Scholar
• Terland O, Flatmark T. Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Neuropharmacology 1999;38(6):879-82
   PubMed Web of Science ®Google Scholar
• Serrano A, Menendez J, Casarejos MJ, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005;49(2):208-19
   PubMed Web of Science ®Google Scholar
• Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003;12(18):2277-91
   PubMed Web of Science ®Google Scholar
• Meredith GE, Switzer RC III, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res 2004;995(1):14-22
   PubMed Web of Science ®Google Scholar
• Hahn J, Tse TE, Levitan ES. Long-term K+ channel-mediated dampening of dopamine neuron excitability by the antipsychotic drug haloperidol. J Neurosci 2003;23(34):10859-66
   PubMed Web of Science ®Google Scholar
• Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005;38(4):171-7
   PubMed Web of Science ®Google Scholar
• Ukai W, Ozawa H, Tateno M, et al. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004;111(6):667-81
   PubMed Web of Science ®Google Scholar
• Saldana M, Bonastre M, Aguilar E, Marin C. Role of nigral NFkappaB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur Neuropsychopharmacol 2006;16(7):491-7
   PubMed Web of Science ®Google Scholar
• Myrianthopoulos NC, Kurland AA, Kurland LT. Hereditary predisposition in drug-induced parkinsonism. Arch Neurol 1962;6:5-9
   PubMed Web of Science ®Google Scholar
• Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 2005;19(3):277-85
   PubMed Web of Science ®Google Scholar
• Theodoulou G, Milner G, Jumaian A. Neuroleptics and family history of Parkinson diseases: case report. East Mediterr Health J 2001;7(3):559-61
   PubMedGoogle Scholar
• Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991;148(10):1322-8
   PubMed Web of Science ®Google Scholar
• Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine. Lancet 1986;2(8511):853-4
   PubMed Web of Science ®Google Scholar
• Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 1990;83(5):525-32
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19(4):379-90
   PubMed Web of Science ®Google Scholar
• Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999;14(1):128-31
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340(10):757-63
   PubMed Web of Science ®Google Scholar
• Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004;37(Suppl 1):S70-8
   PubMedGoogle Scholar
• Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32(4):715-23
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10
   PubMed Web of Science ®Google Scholar
• Ahlenius S, Ericson E. Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats. J Neural Transm 2001;108(4):415-30
   PubMed Web of Science ®Google Scholar